Last reviewed · How we verify
DSP-7888
At a glance
| Generic name | DSP-7888 |
|---|---|
| Sponsor | Sumitomo Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (PHASE3)
- A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (PHASE1)
- Study of DSP-7888 in Patients With Myelodysplastic Syndrome (PHASE1, PHASE2)
- A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas (PHASE1, PHASE2)
- Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DSP-7888 CI brief — competitive landscape report
- DSP-7888 updates RSS · CI watch RSS
- Sumitomo Pharma Co., Ltd. portfolio CI